SHL Medical, a pioneer and technology frontrunner in the self-injection industry, announces its acquisition of Weibel CDS, a medical technology company offering products and solutions for drug delivery and novel packaging.
Weibel was established in Switzerland in 2010 as a private company specialising in customer-funded research and development of affordable, innovative and user-friendly injection systems and devices. Weibel owns an impressive portfolio covering innovative packaging technologies and delivery systems for parenteral drugs for home, point-of-care, and clinical use.
¡°SHL Medical¡¯s acquisition of Weibel is based on a shared passion for innovation and precision. We felt a synergy between Weibel¡¯s cutting-edge technologies and SHL¡¯s experience in commercialising original designs. The integration will strengthen our ability to offer even more advanced drug delivery systems based on human-centred designs and functionality. We look forward to a stronger future based on this shared vision to make self-injection easier for patients worldwide,¡± SHL Medical CEO Ulrich Faessler said.
¡°SHL has always been simultaneously innovative and dependable, factors that have put us in the vanguard of the industry,¡± said Ralph Howald, chief technology officer at SHL Medical. ¡°The addition of Weibel¡¯s talent and range of solutions for high-volume injection will not only add depth to our technical portfolio, but also give us greater reach in the self-injection market.¡±
Weibel CEO Hans Peter Manser said: ¡°We are excited to segue into one of the world¡¯s most prominent solutions providers of drug delivery systems. With SHL¡¯s experience and global outreach, Weibel will be able to accelerate our innovations for safer, easier and faster drug delivery.¡±
SHL Medical is one of the world¡¯s largest providers of autoinjectors. With the acquisition, SHL is expected to expand its portfolio of innovative drug delivery solutions for injection devices.
For additional information, visit:?